Losing Weight RX Open Pharmacoeconomic & Policy Datasets (2026)
Four peer-citable empirical datasets (467 audited records, 21 compiled Apache Parquet splits, and 4 permanent CERN/Zenodo academic DOIs) engineered by the Losing Weight RX Pharmacoeconomics & Consumer Audit Desk for researchers, health-policy journalists, and consumers.
US GLP-1 52-Week Dose-Titration & Cost-Per-Milligram Yield Dataset (2026)
Step-by-step pharmacoeconomic panel dataset tracking 198 clinical dose-escalation observations (0.25-2.4 mg semaglutide and 2.5-15.0 mg tirzepatide) across 18 US telehealth platforms and retail autoinjectors, measuring effective USD per active milligram, step-up penalties, platform membership unbundling, and 52-week cumulative patient expenditure.
US Commercial Insurance GLP-1 Prior-Authorization, Step-Therapy & Cash Bypass Benchmark (2026)
Structured health-policy and payer-formulary audit across 108 US commercial PBM, self-insured employer, ACA Marketplace, Medicare Part D, and direct cash-pay benchmarks evaluating GLP-1 prior-authorization BMI gates, step-therapy durations, lifestyle-app locks, and Q1 deductible out-of-pocket exposure.
Parenteral vs. Sublingual vs. Retail IV Lounge Bioavailability & Cost Index (2026)
Comparative pharmacokinetic and consumer expenditure dataset (110 observations) benchmarking systemic bioavailability percentages, monthly absorbed active milligram yield, and 12-month all-in patient costs across at-home 503A subcutaneous injections, sublingual dissolving tablets, retail IV drip lounges, and oral capsules.
US 50-State + DC Telehealth Modality, Medicaid GLP-1 Coverage & Local Clinic Cost Matrix (2026)
51-jurisdiction US regulatory and geographic price-disparity matrix (50 states plus Washington, DC) indexing state telehealth modality rules (asynchronous vs synchronous video), Medicaid adult obesity GLP-1 coverage, state-employee plan formulary status, non-resident 503A board tiers, and local brick-and-mortar medspa vs online flat-rate savings.